This proof-of-principle study demonstrated that genomic biomarkers with very good sensitivity and specificity for boys with autism spectrum disorder in general pediatric settings can be identified.
Wegbreit et al test the hypothesis that youth with BD (<18 years) would show greater convergence of amygdala hyperactivation and prefrontal cortical hypoactivation vs adults with BD. PubMed and PsycINFO databases were searched for original, task-related coordinate-based fMRI articles. GingerALE software was used to compared pediatric and adult findings.
In a 14-week randomized clinical trial, Freeman and coauthors examine the relative efficacy of family-based cognitive behavior therapy involving exposure plus response prevention vs a family-based relaxation treatment control condition for children 5 to 8 years of age.
Ginsburg et al determine whether acute clinical improvement and treatment type (ie, cognitive behavioral therapy, sertraline, or their combination predicted remission of anxiety and improvement in global functioning at a mean of 6 years after randomization and examine predictors of outcomes at follow-up.